insights_auto
Outlook: 55.6% bullish·0.0% bearish
Go to analysischevron_right
AGIO:NASDAQ
Agios Pharmaceuticals Inc
$31.38
0.00%
(0.00) 1D
Nov 9, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AGIO...
Mkt. cap
1.87B
Avg. vol.
1.29M
Volume
9.00
52-wk high
$46.00
52-wk low
$22.24
EPS
-$6.32
Beta
0.66
Shares outstanding
59.81M
No. of employees
540
Mkt. cap
1.87B
Avg. vol.
1.29M
Volume
9.00
52-wk high
$46.00
52-wk low
$22.24
EPS
-$6.32
Beta
0.66
Shares outstanding
59.81M
No. of employees
540
News stories
From web sources and news partners
CNBC
·
2 hours ago
Anthropic sets price range of $70 to $78 in upcoming IPO as AI lab marches towards Nasdaq
The Northern Virginia Daily
·
21 minutes ago
Wall Street mixed in early trading ahead of a new peek at inflation
Investing.com
·
22 minutes ago
S&P 500 market positioning risks ahead of CPI and NVIDIA earnings
Reuters
·
1 hour ago
Nasdaq futures slip with Nvidia woes, Anthropic IPO in focus
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc